Breast Cancer Liquid Biopsy Market Outlook, Industry Demand Analysis Report

The global breast cancer liquid biopsy market size reached USD 5.14 Billion in 2022 and is expected to register a revenue CAGR of 22.7% during the forecast period, according to latest analysis by Emergen Research. Rising demand for minimally invasive approaches in oncology is driving revenue growth of the market. Liquid biopsy is a non-invasive method for identification of tumor markers, either as an alternative for patients whose tissue is unable to be biopsied, or to evaluate drug response. It is less costly than tumor tissue biopsy and offers an accurate understanding of genomic landscape of a tumor. Liquid biopsy is witnessing increased demand in diagnosis of solid and other tumors. In addition, one of the other key factors driving market revenue growth is expansion of research & development into the creation of breast cancer liquid biopsy solutions to address breast-related issues and conditions. Development of novel technologies is made possible by the increasing number of research activities carried out by an array of institutions around the world. Effectiveness of newer technologies makes it easier for them to enter the market.

For more details of the Breast Cancer Liquid Biopsy Market Report, visit @ https://www.emergenresearch.co....m/industry-report/br